The DPH5 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the DPH5 gene has been disrupted in the A-549 human lung adenocarcinoma cell line. This polyclonal pool contains a heterogeneous mixture of edited alleles, offering a robust loss-of-function model for studying diphthamide biosynthesis without relying on single-cell clonal isolation. The polyclonal format preserves genetic diversity while effectively eliminating functional DPH5 protein across the population, making it suitable for pooled functional genomics and phenotypic screening applications.
The A-549 host cell line is derived from human lung adenocarcinoma tissue and serves as a widely utilized model for alveolar type II epithelial cells. These adherent epithelial cells retain key characteristics of lung epithelium, including surfactant production and barrier function, making them a valuable system for respiratory research, cancer biology, and drug transport studies. The A-549 background provides a relevant context for investigating DPH5 function within a lung-derived epithelial environment, particularly given the importance of translational control in cancer cell proliferation and stress responses.
DPH5 encodes diphthamide synthase, catalyzing the transfer of a trimethylamino moiety from S-adenosyl methionine (SAM) to histidine-715 of translation elongation factor 2 (eEF2), the first step in diphthamide biosynthesis. This modification is critical for eEF2-mediated ribosomal translocation during protein synthesis. DPH5 acts in a pathway with interacting factors DPH1, DPH2, DPH3, and DPH4, which together generate the diphthamide, while downstream factors DPH6 and DPH7 may process it further. General transcription factors regulate DPH5 expression, and its activity directly modulates eEF2 function and global translation elongation rates. The diphthamide modification also confers sensitivity to diphtheria toxin, which ADP-ribosylates the modified histidine.
Disruption of DPH5 in A-549 cells creates a unique model for dissecting diphthamide-dependent processes within an epithelial cancer context. Because A-549 cells are naturally sensitive to diphtheria toxin due to endogenous diphthamide modification, DPH5 knockout confers robust resistance, enabling studies of toxin entry, trafficking, and killing mechanisms. Furthermore, loss of diphthamide on eEF2 may alter translation fidelity and elongation dynamics, providing a platform to investigate how translational control contributes to cancer cell fitness. Given the association of DPH5 mutations with neurodevelopmental syndromes, this model may also facilitate the exploration of tissue-specific requirements for diphthamide modification, although A-549 cells are of lung origin, they allow for comparative studies across cell types.
Researchers can use these polyclonal DPH5 knockout cells for diphtheria toxin resistance assays, western blotting for DPH5, puromycin incorporation to measure translation elongation, and mass spectrometry to assess diphthamide on eEF2. Applications include studies of toxin susceptibility, protein synthesis regulation, diphthamide complex interactions, and modeling of related disorders. For details, contact Ascent Research.
